Document:

Exhibit 10.1

SINCLAIR BROADCAST GROUP, INC.

STOCK APPRECIATION RIGHT AGREEMENT

THIS STOCK APPRECIATION RIGHT AGREEMENT
(this “Agreement”) is made and entered into as of this 2nd day of April, 2007
(the “Grant Date”) between Sinclair Broadcast Group, Inc., a Maryland
corporation (the “Company”), and David D. Smith (“Smith”).

RECITALS

WHEREAS, the Company had adopted
the 1996 Long-Term Incentive Plan of Sinclair Broadcast Group, Inc. (the “Plan”)
to reward certain key individuals for making contributions to the Company and
its subsidiaries by enabling them to acquire shares of Class A Common Stock,
par value $.01 per share (“Common Stock”), of the Company; and

WHEREAS, the Company desires to
grant to Smith stock-settled stock appreciation rights in the amount of two
hundred thousand (200,000) shares of Common Stock (the “SARs”) pursuant to the
Plan and upon the terms and subject to the conditions hereinafter set forth.

AGREEMENTS

NOW, THEREFORE, IN CONSIDERATION OF
the foregoing premises, the parties to this Agreement agree as follows:

1.             Grant of
SARs.  Subject to the
terms and conditions set forth in this Agreement, the Company hereby grants to
Smith the right to receive Common Stock of the Company equal in value to the
difference between the SARs’ base value of Fifteen Dollars and Seventy Eight
Cents ($15.78) per SAR, which is the fair market value of the Common Stock on
the date of grant under the Plan, and the per share closing price of the
Company’s Common Stock on the date of exercise.

2.             Relationship
to Plan.  The SARs are
issued in accordance with and subject to all of the terms, conditions, and
provisions of the Plan, as amended from time to time and administrative
interpretations thereunder, if any, which have been adopted by the Committee
thereunder and are in effect on the date hereof.  Except as defined herein or otherwise stated,
capitalized terms shall have the same meanings ascribed to them under the Plan.

3.             Termination
of SARs.  The SARs hereby
granted shall terminate and be of no force and effect with respect to any
shares of Common Stock not previously acquired by Smith on the tenth (10th)
anniversary of the Grant Date.

4.             Exercise
of SARs.  Subject to the
limitations herein and in the Plan, the SARs may be exercised with respect to
the shares of Common Stock, in whole or in part, at any time on

or prior to the
tenth (10th) anniversary of the Grant Date, regardless of Smith’s service
status, by written notice to the Company at its principal executive office.

5.             Transferability.  The SARs shall not be transferable except by
will or by the laws of descent and distribution.  During Smith’s lifetime, the SARs may be
exercised only by Smith.  No assignment
or transfer of the SARs, whether voluntary or involuntary, by operation of law
or otherwise, except a transfer by will or by the laws of descent or
distribution, shall vest in the assignee or transferee any interest or right
whatsoever in the SARs.

6.             No Rights
as Stockholder.  Smith
shall not have any rights as a stockholder of the Company with respect to any
of the shares subject to the SARs, except to the extent that such shares shall
have been acquired by and transferred to Smith.

7.             Dissolution
or Merger.  Upon the
dissolution or liquidation of the Company, a merger or consolidation in which
the Company is not the surviving corporation, or a transaction in which another
individual or entity becomes the owner of fifty percent (50%) or more of the
total combined voting power of all classes of stock of the Company, the
unexercised portion of the SARs shall terminate, but Smith shall have the right
to exercise the unexercised portion of the SARs, immediately prior to such
event.

8.             Withholding
for Tax Purposes.  Any
amount of Common Stock that is payable or transferable to Smith hereunder may
be reduced by any amount or amounts which the Company is required to withhold
under the then applicable provisions of the Internal Revenue Code of 1986, as
amended, or its successors, or any other federal, state, or local tax
withholding requirement.  If Smith does
not elect to satisfy withholding requirements in this fashion, the issuance of
the shares of Common Stock transferable to Smith hereunder shall be contingent
upon Smith’s satisfaction of any withholding obligations that may apply and
Smith’s presentation of evidence satisfactory to the Board that such
withholding obligations have been satisfied.

9.             Notice.  Whenever any notice is required or permitted
hereunder, such notice must be in writing and personally delivered or sent by
mail.  Any notice required or permitted
to be delivered hereunder will be deemed to be delivered on the date that it is
personally delivered or, whether actually received or not, on the third (3rd)
business day after it is deposited in the United States mail, certified or
registered, postage prepaid, addressed to the person who is to receive it at
the address that such person has heretofore specified by written notice
delivered in accordance herewith.  The
Company or Smith may change, at any time and from time to time, by written notice
to the other, the address that it or he had therefore specified for receiving
notices.  Until changed in accordance
herewith, the Company and Smith specify their respective addresses as set forth
below:

	
  

  	
  Company:

  	
  Sinclair Broadcast Group, Inc.

  
	
   

  	
   

  	
  10706 Beaver Dam
  Road

  
	
   

  	
   

  	
  Cockeysville,
  Maryland 21030

  
	
   

  	
   

  	
  Attn:

  	
  David B. Amy,

  
	
   

  	
   

  	
   

  	
  Executive Vice President

  

 

 

	
  

  	
  with copy to:

  	
  Sinclair Broadcast Group, Inc.

  
	
   

  	
   

  	
  10706 Beaver Dam Road

  
	
   

  	
   

  	
  Cockeysville, Maryland 21030

  
	
   

  	
   

  	
  Attn:
  

  	
  Vice President/General Counsel

  
	
   

  	
   

  	
   

  	
   

  
	
   

  	
  Smith:

  	
  David D. Smith

  
	
   

  	
   

  	
  c/o Sinclair
  Broadcast Group, Inc.

  
	
   

  	
   

  	
  10706 Beaver Dam
  Road

  
	
   

  	
   

  	
  Cockeysville,
  Maryland 21030

  

 

10.           Amendment.  Notwithstanding any other provision hereof,
this Agreement may not be supplemented or amended from time to time without the
consent of Smith.

11.           Governing Law.  This Agreement shall be governed by and
construed and enforced in accordance with the laws of the State of Maryland
applicable to agreements made and to be performed entirely in Maryland.

12.           Counterparts.  This Agreement may be executed in multiple
counterparts.  The Company and Smith may
sign any number of copies of this Agreement. 
Each signed copy shall be an original, but all of them together
represent the same agreement.

[REST OF PAGE LEFT
INTENTIONALLY BLANK

— SIGNATURES ON FOLLOWING PAGE]

IN WITNESS WHEREOF, the Company
and Smith have caused this Agreement to be executed as of the date first above
written.

	
  WITNESS:

  	
   

  	
   

  	
   

  	
  SINCLAIR BROADCAST GROUP, INC.

  
	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  
	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  
	
  /s/ Cam Smart

  	
   

  	
   

  	
  By:

  	
   

  	
  /s/ David B. Amy

  	
  (SEAL)

  
	
   

  	
   

  	
   

  	
  Name:

  	
   

  	
  David B. Amy

  	
   

  
	
   

  	
   

  	
   

  	
  Title:

  	
   

  	
  Executive Vice President

  
	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  
	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  
	
  /s/ Cam Smart

  	
   

  	
   

  	
   

  	
   

  	
  /s/ David D. Smith 

  	
  (SEAL)

  
	
   

  	
   

  	
   

  	
   

  	
   

  	
  David D. SmithExhibit 10.1

TERMINATION OF

CONSULTING AGREEMENT

Reference is made to the Consulting Agreement dated
October 4, 2004 between MOMENTA PHARMACEUTICALS, INC., (the “Company”) and Bennett
M. Shapiro (“Consultant”), as amended (collectively, the “Agreement”). 
Capitalized terms used herein and not otherwise defined shall have the meanings
given such terms in the Agreement.

The parties hereby agree to terminate Agreement
effective as of March 30, 2007. 
Notwithstanding anything to the contrary, Sections 3 (Developments) and
4 (Confidentiality) shall survive such termination.

Agreed to as of the date of
last signature below.

	
  CONSULTANT

  	
   

  	
  MOMENTA PHARMACEUTICALS, INC.

  
	
  /s/ Bennett M. Shapiro

  	
   

  	
  By: 

  	
  /s/ Craig A. Wheeler

  
	
  Bennett M. Shapiro

  	
   

  	
  Print Name: Craig A.
  Wheeler

  
	
  Date:

  	
   

  	
  Title: President &
  CEO

  
	
   

  	
   

  	
  Date: March 30, 2007Exhibit
10.2

	
  

  	
   

  	
  Georg
  Rieder

  Managing Director

  	
   

  	
  Sandoz NV

  Pietermaai 15

  Willemstad, Curacao

  Netherlands Antilles
 Phone +599-9-737-1721

  Fax +599-9-736-4065

  E-mail georg.rieder

  @sandoz.com

  www.sandoz.com

  

 

February 1, 2007

VIA
OVERNIGHT MAIL

Momenta Pharmaceuticals Inc.

675 West Kendall Street

Cambridge, Massachusetts  02142

Re:                 Collaboration
and License Agreement between Sandoz N.V. (f/k/a Biochemie West Indies, N.V.),
Sandoz Inc. (f/k/a Geneva Pharmaceuticals, Inc.),  and Momenta Pharmaceuticals Inc., dated
November 1, 2003 (the “Collaboration Agreement”); Assignment from Sandoz N.V.
to Sandoz AG and removal of Sandoz GmbH as Guarantor

Gentlemen,

All
terms used, but not defined, herein have the meanings ascribed to them in the
Collaboration Agreement.

Sandoz
N.V. is informing Momenta that it has assigned all of its rights and
obligations, including without limitation any license rights it had under
Momenta IP and Momenta’s rights in the Joint Collaboration IP, under the
Collaboration Agreement to Sandoz AG, and Sandoz AG has agreed to assume all of
the rights and obligations of Sandoz N.V. under the Collaboration
Agreement.  Sandoz N.V. desires the
written consent of Momenta to such assignment pursuant to Section 14.3(b) of
the Collaboration Agreement.  Sandoz AG
is a Swiss corporation and an Affiliate (as defined in the Collaboration
Agreement) of Sandoz N.V., having its office at Lichtstrasse 35, CH 4056 Basel,
Switzerland.  Sandoz N.V. and Sandoz AG
each represent that Sandoz N.V. has assigned to Sandoz AG all right, title and
interest in and to the Sandoz IP and Sandoz N.V.’s rights in the Joint
Collaboration IP.  By execution of this
letter, all of the parties hereto also agree that the guarantee of Sandoz GmbH
to the Collaboration Agreement is hereby rendered null and void and of no
further force or effect.  Please duly
sign and return two copies of this letter to Sandoz AG, Attention:  Peter Rupprecht, at the above mentioned

 

address, which
shall forthwith be substituted for the notice address of Sandoz N.V. in Section
14.5 of the Collaboration Agreement. 
Thank you.

Best regards,

	
  Sandoz N.V.

  	
   

  	
  Sandoz AG 

  
	
   

  	
   

  	
   

  	
   

  	
   

  
	
  By:

  	
  /s/ Georg Rieder

  	
   

  	
  By: 

  	
  /s/ Barbara Kessler

  
	
   

  	
  Name: Georg Rieder

  	
   

  	
   

  	
  Name: Barbara Kessler

  
	
   

  	
  Title: Managing Director 

  	
   

  	
   

  	
  Title: Member of the Board of Directors 

  
	
   

  	
   

  	
   

  	
   

  	
   

  
	
  By:

  	
  /s/ Felix Eichhorn                         /s/ Jurgen Vierkotter
  

  	
   

  	
  By:

  	
  /s/ [illegible] 

  
	
   

  	
  Name: Felix Eichhorn                       Jurgen Vierkotter 

  	
   

  	
   

  	
  Name: 

  
	
   

  	
  Title: Authorized signatory              Authorized Signatory

  	
   

  	
   

  	
  Title:

  
	
   

  	
   

  	
   

  	
   

  	
   

  
	
  Sandoz GmbH

  	
   

  	
  SANDOZ INC.

  
	
   

  	
   

  	
   

  	
   

  	
   

  
	
  By:

  	
  /s/ E. Dolejsi Jegerbaghern

  	
   

  	
  By:

  	
  /s/ Eric Pomerantz

  
	
   

  	
  Name: E. Dolejsi Jegerbaghern

  	
   

  	
   

  	
  Name: Eric Pomerantz 

  
	
   

  	
  Title: Head, Legal Head SDC 

  	
   

  	
   

  	
  Title: VP & General Counsel

  
	
   

  	
   

  	
   

  	
   

  	
   

  
	
  By:

  	
   

  	
   

  	
   

  	
   

  
	
   

  	
  Name: 

  	
   

  	
   

  	
   

  
	
   

  	
  Title:

  	
   

  	
   

  	
   

  
	
   

  	
   

  	
   

  	
   

  	
   

  
	
  Acknowledged and Agreed:

  	
   

  	
   

  	
   

  
	
  Momenta Pharmaceuticals, Inc.

  	
   

  	
   

  	
   

  
	
   

  	
   

  	
   

  	
   

  
	
  By:

  	
  /s/ Craig A. Wheeler

  	
   

  	
   

  	
   

  
	
   

  	
  Name:

  	
   

  	
   

  	
   

  
	
   

  	
  Title:

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00123-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00123-of-00352.parquet"}], [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00123-of-00352.parquet"}]]